The results of this study indicate that miR-29b inhibits the proliferation and deterioration of NSCLC cells by targeting FEM1B and inhibiting the activation of the FOXO1/AKT pathway. This evidence concerns the gene FOXO1 and non-small cell lung carcinoma.